title: Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
abstract: Menstrual cycle activity is the most important risk factor for sporadic serous ovarian carcinoma, whereas a germ-line mutation in BRCA1 is the most important risk factor for the familial form. Given the rarity of BRCA1 mutations in sporadic ovarian cancers, we hypothesized that BRCA1 influences the menstrual cycle in a way that mimics the factors underlying sporadic ovarian cancer predisposition, making BRCA1 mutations redundant in such cancers. We compared the length of each phase of the estrus cycle (equivalent to the human menstrual cycle) and of circulating levels of estradiol in control mice and in mice carrying a Brca1 mutation in their ovarian granulosa cells, two thirds of which develop ovarian or uterine epithelial tumors. We also compared the length of the different phases of the cycle in mutants that subsequently developed tumors with those in mutants that remained tumor-free. Mutant mice as well as oophorectomized wild-type mice harboring mutant ovarian grafts showed a relative increase in the average length of the proestrus phase of the estrus cycle, which corresponds to the estrogen-dominated follicular phase of the human menstrual cycle. Total circulating levels of estradiol were also increased in mutant mice injected with pregnant mare serum gonadotropins. The relative increase in proestrus length was highest in mutant mice that subsequently developed reproductive epithelial tumors. We conclude that loss of a functional Brca1 increases murine ovarian epithelial tumor predisposition by increasing estrogen stimulation in the absence of progesterone, recapitulating conditions associated with sporadic ovarian cancer predisposition in humans.
authors.affiliation: Department of Pathology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
authors.forename: Hao
authors.initials: H
authors.lastname: Hong
authors.forename: Hai-Yun
authors.initials: HY
authors.lastname: Yen
authors.forename: Amy
authors.initials: A
authors.lastname: Brockmeyer
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Rajas
authors.initials: R
authors.lastname: Chodankar
authors.forename: Malcolm C
authors.initials: MC
authors.lastname: Pike
authors.forename: Frank Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: Robert
authors.initials: R
authors.lastname: Maxson
authors.forename: Louis
authors.initials: L
authors.lastname: Dubeau
mesh_terms: D000818:Animals; D004958:Estradiol / Q000097:blood / Q000235:genetics; D030762:Estrous Cycle / Q000235:genetics*; D005260:Female; D020868:Gene Silencing; D019398:Genes, BRCA1 / Q000502:physiology*; D020022:Genetic Predisposition to Disease; D006107:Granulosa Cells / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D010051:Ovarian Neoplasms / Q000097:blood / Q000235:genetics*; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D012307:Risk Factors
chemical_list: D004958:Estradiol